Price
No data yet.
Social Signal Score
Analyst Ratings
9 analystsRevenue
$3.38M+262.70%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Matthew Roden
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 79
- Beta
- 0.45
- Country
- US
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- 8.26
Financials
AKTS has only 5 quarterly periods on file — the charts below show the full history available.
Revenue
$3.38M+262.7%Net Income
$-24.14MEBITDA
$-28.02MFree Cash Flow
$-21.85MEPS (diluted)
$-0.44Shares Outstanding (diluted)
55.32M+5.3%Operating Expenses
$31.40MCash & Debt
$517.32MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $6.50M | $-63.73M | $-1.19 |
| 2024 | $1.49M | $-43.98M | $-1.26 |
| 2023 | $0.00 | $-28.64M | $-0.82 |
| 2022 | $0.00 | $-17.93M | $-0.51 |
Valuation
AKTShas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
100-23.08%Social Signal Score
Mentions (3)
- Newsglobenewswire.com·5d ago·Neutral
… in metastatic castration-resistant prostate cancer (mCRPC); preliminary data expected in 2027 BOSTON, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Aktis Oncology, Inc. (NASDAQ:AKTS) (“Aktis” or the “Company”), a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large populations, today announced the initiation of the Phase 1b BActinium-2 trial of AKY-25191 in patients with NSCLC and other B7-H3 expressing solid tumor types. The BActinium-2 …
View source ↗ - Newsseekingalpha.com·19d ago·Positive
Aktis Oncology, Inc. (AKTS) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript Aktis Oncology, Inc. (AKTS) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
View source ↗ - Newsinvestopedia.com·52d ago·Positive
Bank of America Sees Bargains in These 16 Knocked-Down AI Stocks A pullback in the AI trade has created opportunities for bargain-hunting investors, according to analysts at Bank of America.
View source ↗
Earnings
Thu, Nov 12(in 5 weeks)
Consensus estimate $-0.47 per share
Typical surprise -9.4% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 13$-0.44 vs $-0.43miss
- Mon, May 11$-0.38 vs $-0.31miss
- Mon, Mar 30$-18.19 vs $-21.59beat
- Wed, Dec 3$-1.39 vs $-0.11miss
- Thu, Nov 14$-0.04 vs $-0.10beat
- Mon, May 13$-0.14 vs $-0.12miss
Estimates and results for AKTS via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by AKTS officers and directors.
- Bought
- —
- Sold
- $259k
0 trades
2 trades
- Czibere Akossold
- Czibere Akossold
3 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in AKTS.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.